Anthropic’s Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis, to its Board of Directors. Narasimhan brings over two decades of experience in medicine and global health, having overseen the development and approval of more than 35 novel medicines. His experience aligns with Anthropic’s mission of utilizing AI to enhance healthcare and improve human life, a field where he has emphasized AI’s role in tackling complex scientific challenges. The Long-Term Benefit Trust aims to ensure that Anthropic responsibly balances its commitment to shareholders with its public mission, an approach that Narasimhan is expected to support through his expertise in the responsible stewardship of breakthrough science.

Novartis: Novartis is a global medicines company focused on innovative pharmaceuticals through strategic R&D transformation. It integrates AI to augment scientists and speed up drug development processes. CEO Vas Narasimhan’s recent board appointment at Anthropic highlights synergies between its AI-driven healthcare advancements and responsible technology governance.
Anthropic: Anthropic is an AI safety and research company building reliable, interpretable, and steerable AI systems like the Claude assistant. Recently, it released economic index reports on Claude usage and advanced capabilities in agentic coding and long-horizon tasks. Its Long-Term Benefit Trust appointed Vas Narasimhan to the board, making Trust-appointed directors a majority to align governance with responsible AI development for humanity’s benefit.
Vas Narasimhan: Vas Narasimhan is a physician-scientist serving as CEO of Novartis, with extensive experience in global health and regulated pharmaceutical innovation. In early 2026, he discussed AI’s potential to transform pharma by accelerating solutions in disease biology and medicine design. Appointed to Anthropic’s board by its Long-Term Benefit Trust, he brings expertise in safely deploying powerful technologies at scale.

`json
{
“AI in Pharma”: “Novartis uses AI to enhance R&D by augmenting human teams rather than replacing them.”,
“Healthcare AI Outlook”: “Novartis CEO Vas Narasimhan emphasized AI’s role in addressing complex scientific challenges in medicine.”
}
`